Centr Georges Francois Leclerc

This site in Dijon, France, is highly active in medical oncology, with research focused on neoplasms and solid tumors. Many trials are designed to test new cancer therapies and improve outcomes for people with advanced disease.

• Breast cancer, especially HER2-positive, HER2-negative, and triple-negative disease
• Lung cancer, including non-small cell lung cancer and mutation-driven subtypes
• Ovarian, endometrial, and other gynecologic cancers
• Prostate cancer and other genitourinary cancers

The research often evaluates whether targeted treatments, immunotherapy, or treatment combinations can improve survival, delay relapse, or better control metastatic disease.

A major part of the portfolio centers on respiratory tract diseases, especially non-small cell lung cancer and small-cell lung cancer. These studies aim to refine treatment for newly diagnosed, advanced, and recurrent disease.

• Advanced and metastatic non-small cell lung cancer
• Mutation-specific lung cancer, including EGFR, ALK, ROS1, MET, and KRAS G12C
• Small-cell lung cancer and selected locally advanced cases
• Testing immunotherapy, targeted therapy, and combination approaches

The goal is to improve response rates, extend progression-free survival, and identify better options for patients whose lung cancers have become harder to treat.

The site has a strong focus on breast cancer, particularly ER-positive, HER2-negative, HER2-positive, and triple-negative breast cancer. Several studies are exploring how to personalize care using tumor markers and blood-based tests.

• Early and metastatic breast cancer
• HER2-positive and HER2-low breast cancer
• HR-positive disease with PIK3CA or BRCA-related alterations
• Circulating tumor DNA and imaging to guide treatment decisions

These trials are designed to test new therapies, study de-escalation strategies in selected patients, and improve the precision of treatment selection.

Research in digestive system diseases is broad, covering colorectal cancer, gastric cancer, pancreatic cancer, and biliary tract cancer. The focus is on both advanced disease and settings where surgery or combined treatment is still possible.

• Colorectal cancer, including biomarker-defined subgroups
• Gastric, gastroesophageal junction, and esophageal cancers
• Pancreatic cancer and biliary tract cancer
• Evaluating immunotherapy, targeted therapy, and treatment combinations

These studies aim to improve survival, reduce recurrence, and find more effective options for hard-to-treat gastrointestinal cancers.

The portfolio also includes extensive work in genitourinary cancers, with a particular emphasis on prostate cancer and urothelial carcinoma. Research at Centr Georges Francois Leclerc is examining both advanced disease and earlier relapse prevention.

• Metastatic and castration-resistant prostate cancer
• Hormone-sensitive prostate cancer with molecular imaging or biomarker selection
• Bladder and urothelial cancers
• Testing new radioligand, hormonal, and immunotherapy approaches

The main purpose is to improve disease control, delay progression, and support more tailored treatment decisions for patients with recurrent or metastatic urologic cancers.

A substantial part of the research program addresses soft tissue sarcoma, bone sarcoma, melanoma, and a wide range of advanced solid tumors. These studies often involve patients with rare or aggressive cancers.

• Soft tissue and bone sarcomas
• Melanoma and other advanced skin-related cancers
• Rare and biomarker-selected solid tumors
• Assessing new combinations of immunotherapy and targeted treatment

The research aims to identify more active therapies, improve tumor control, and offer options for cancers with limited standard treatments.

The site is active in female urogenital diseases, especially ovarian, endometrial, and cervical cancers. There is also interest in HPV-related malignancies and precancerous lesions.

• Ovarian, endometrial, cervical, and vulvar cancers
• HPV-16-positive recurrent or metastatic cancers
• High-grade lesions linked to human papillomavirus
• Evaluating immunotherapy, maintenance treatment, and relapse prevention

These trials are intended to improve long-term disease control and explore more effective treatment strategies for both advanced cancer and high-risk precancerous disease.

Research also extends to nervous system diseases, including aggressive brain tumors such as glioblastoma and diffuse midline glioma. The site participates in studies for rare and difficult-to-treat cancers where better options are urgently needed.

• Diffuse intrinsic pontine glioma and other diffuse midline gliomas
• Recurrent glioblastoma
• Rare solid tumors with limited standard therapies
• Testing new approaches that may improve survival and disease control

These trials focus on finding more effective treatments for tumors with poor prognosis and few established therapeutic pathways.

Beyond treatment studies, the site also explores diagnostic techniques, surgery-related care, and supportive measures across cancer types. This includes work aimed at improving how clinicians detect disease changes and manage patients around treatment.

• Imaging and biomarker-based diagnostics
• Perioperative care in digestive cancer surgery
• Supportive care and treatment tolerance during cancer therapy
• Evaluating ways to improve decision-making and patient outcomes

This part of the research portfolio supports better diagnosis, safer care, and more individualized treatment planning across oncology.